Immunome 亏损且未达到预期;Immunocore 报告了意外的利润并超出预期。 Immunome lost money and missed estimates; Immunocore reported a surprise profit and beat expectations.

Immunome(IMNM)报告季度损失每股0.65美元,损失估计数为0.08美元,股票负收益为77.37%,净利润为1 687.08%。 Immunome (IMNM) reported a quarterly loss of $0.65 per share, missing estimates by $0.08, with a negative return on equity of 77.37% and net margin of -1,687.08%. 库存量超过平均数量,跌至15.24美元。 The stock fell to $15.24 on above-average volume. 尽管华尔街Zen将“销售”降级, 协商一致的评分仍为“Moderate Buy”, 目标为23.20美元。 Despite a downgrade to "sell" by Wall Street Zen, the consensus rating remains "Moderate Buy" with a $23.20 target. 该公司正在第3阶段对脱氧核糖核酸肿瘤试验中推进AL102,并拥有若干临床预科方案。 The company is advancing AL102 in a Phase 3 trial for desmoid tumors and has several preclinical programs. Imnunocore(IMCR)出乎意料的利润为每股0.2美元,比重估计为0.32美元,收入比上一年增加29.2%。 Immunocore (IMCR) posted a surprise profit of $0.02 per share, beating estimates by $0.32, with revenue up 29.2% year-over-year. 股份升至33.50美元,得到分析家的强烈兴趣和60.89美元平均价格目标的支持。 Shares rose to $33.50, supported by strong analyst interest and a $60.89 average price target. 公司市场KIMMTRAK用于乳腺瘤,目前正在第2/3阶段试验Tebentafusp,以测试高级乳腺瘤。 The company markets KIMMTRAK for uveal melanoma and is testing tebentafusp in a Phase 2/3 trial for advanced cutaneous melanoma.